Gujarat Themis Biosyn soars on signing pact to acquire Sanofi`s anti TB, anti-infective brands
Gujarat Themis Biosyn is currently trading at Rs. 330.25, up by 7.30 points or 2.26% from its previous closing of Rs. 322.95 on the BSE.
The scrip opened at Rs. 330.25 and has touched a high and low of Rs. 335.40 and Rs. 327.10 respectively. So far 745 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 479.45 on 27-Oct-2025 and a 52 week low of Rs. 225.75 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 339.45 and Rs. 313.10 respectively. The current market cap of the company is Rs. 3519.03 crore.
The promoters holding in the company stood at 70.86%, while Institutions and Non-Institutions held 2.98% and 26.16% respectively.
Gujarat Themis Biosyn has signed asset purchase agreement to acquire a portfolio of anti-tuberculosis (TB) and anti-infective brands from Sanofi, the French-holding company of the Sanofi group, headquartered in Paris. The company now looks forward to working with Sanofi to ensure a seamless transition and continuity of supply to patients globally.
The acquisition, which remains subject to obtaining antitrust and foreign direct investment approvals in applicable jurisdictions, would involve 13 established branded generic products with a strong presence across more than 55 countries in Europe, the Middle East and Africa. The concerned portfolio reported net sales of around 62 million euro for the year ended 2025. The acquisition would include marketing authorizations, brands, regulatory dossiers, and inventory and associated commercial rights. The transaction does not involve the transfer of manufacturing facilities or employees, making it a capital-efficient and asset light expansion for the company.
This move would represent a significant step in the company’s strategy to strengthen its global pharmaceuticals platform and expand its presence in the anti-infective segment. The transaction would provide immediate access to regulated and semi-regulated markets, enabling the company to enhance its international footprint. The consideration for the transaction would be 158 million euro, payable in cash at closing and is expected to be funded by an optimal mix of debt and equity. The transaction is expected to close by the end of Q3FY27 (Quarter Ending December 31, 2026).
